← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Revenue increased 0.0% to $41.1M, while Net income decreased 177.6% to ($22.4M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $41.1MWatch
- Profitability — Net income ($22.4M)Watch
- Cash generation — Free cash flow ($22.8M)Note
- Accounting — Formula distress score · manipulation flag raised · earnings quality greyWatch
- Insiders — 0 buys; 8 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Business
Equillium, Inc.: If we are unable to establish marketing and sales capabilities or enter into agreements with contracted third parties to market and sell any of our products if and when approved, we may not be able to generate product revenue; The manufacture of pharmaceutical products is complex and we may encounter difficulties in production, distribution and delivery of our product candidates.
Where the revenue comes from
Fiscal 2024, as Equillium, Inc. reports it. History and quarterly detail are in the app.
- Research And Development Services$28.3M
- Upfront Payment Amortization$12.8M
Leadership changes
From Equillium, Inc.'s own filings, the day they're filed.
- Bala Manian · Directors · departureeff. 2025-10-01
- Mark Pruzanski · chairperson · appointmenteff. 2025-09-30
- Daniel M. Bradbury · President · appointmenteff. 2025-09-30
Latest filings
- 8-K · Company announcement2026-08-13
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-05-29
- 10-Q · Quarterly report2026-05-13
- 8-K · Company announcement2026-05-13
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Equillium, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.